Coherus Oncology (CHRS) Short Interest Ratio & Short Volume $1.16 -0.02 (-1.69%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$1.17 +0.01 (+0.86%) As of 08/29/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Coherus Oncology Short Interest DataCoherus Oncology (CHRS) has a short interest of 32.34 million shares, representing 30.35% of the float (the number of shares available for trading by the public). This marks a 3.55% increase in short interest from the previous month. The short interest ratio (days to cover) is 23.1, indicating that it would take 23.1 days of the average trading volume of 1.34 million shares to cover all short positions.Current Short Interest32,340,000 sharesPrevious Short Interest31,230,000 sharesChange Vs. Previous Month+3.55%Dollar Volume Sold Short$30.41 millionShort Interest Ratio23.1 Days to CoverLast Record DateJuly 31, 2025Outstanding Shares116,230,000 sharesShort Percent of Float30.35%Today's Trading Volume499,566 sharesAverage Trading Volume1,336,872 sharesToday's Volume Vs. Average37% Short Selling Coherus Oncology? Sign up to receive the latest short interest report for Coherus Oncology and its competitors with MarketBeat's FREE newsletter. Email Address Get Report View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartCHRS Short Interest Over TimeCHRS Days to Cover Over TimeCHRS Percentage of Float Shorted Over Time Coherus Oncology Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 7/31/202532,340,000 shares $30.41 million +3.6%30.3%23.1 $0.94 7/15/202531,230,000 shares $26.53 million -2.2%N/A22.5 $0.85 6/30/202531,940,000 shares $23.36 million No Change30.0%21.2 $0.73 6/15/202531,940,000 shares $24.33 million -1.8%30.0%20.1 $0.76 5/31/202532,530,000 shares $25.24 million -1.8%30.4%18 $0.78 5/15/202533,120,000 shares $25.44 million +1.7%30.9%18.1 $0.77 4/30/202532,570,000 shares $33.55 million -1.4%N/A18.8 $1.03 4/15/202533,030,000 shares $35.01 million +1.7%30.9%16.6 $1.06 3/31/202532,490,000 shares $26.22 million -0.2%30.4%16.7 $0.81 3/15/202532,550,000 shares $29.95 million +5.8%30.4%15.7 $0.92 Get the Latest News and Ratings for CHRS and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Coherus Oncology and its competitors with MarketBeat's FREE daily newsletter. 2/28/202530,770,000 shares $34.15 million -3.3%28.7%12.4 $1.11 2/15/202531,810,000 shares $37.54 million +2.9%29.7%6.9 $1.18 1/31/202530,900,000 shares $36.46 million +3.7%N/A6.2 $1.18 1/15/202529,790,000 shares $43.49 million -3.0%N/A6 $1.46 12/31/202430,720,000 shares $42.39 million -1.1%N/A6.2 $1.38 12/15/202431,070,000 shares $50.02 million +1.1%N/A6.1 $1.61 11/30/202430,720,000 shares $37.48 million -7.0%N/A6 $1.22 11/15/202433,040,000 shares $24.58 million +4.9%N/A11.7 $0.74 10/31/202431,510,000 shares $23.47 million +5.6%N/A12.6 $0.75 10/15/202429,850,000 shares $27.17 million +6.8%N/A13.4 $0.91 9/30/202427,960,000 shares $29.08 million +11.4%N/A13 $1.04 9/15/202425,090,000 shares $32.62 million -0.2%N/A12.6 $1.30 8/31/202425,150,000 shares $34.96 million +4.8%N/A14.7 $1.39 8/15/202424,010,000 shares $37.22 million +6.0%N/A13.6 $1.55 7/31/202422,660,000 shares $34.90 million -1.6%N/A13.1 $1.54 7/15/202423,020,000 shares $37.98 million -0.1%N/A14 $1.65 6/30/202423,040,000 shares $39.86 million +3.8%N/A13.8 $1.73 6/15/202422,200,000 shares $37.52 million +0.6%N/A13.2 $1.69 5/31/202422,060,000 shares $40.15 million +1.3%N/A11.4 $1.82 5/15/202421,780,000 shares $47.48 million +0.4%N/A9.9 $2.18 4/30/202421,690,000 shares $42.51 million +0.7%N/A9.4 $1.96 4/15/202421,530,000 shares $47.37 million -8.2%N/A7.6 $2.20 3/31/202423,450,000 shares $56.05 million -9.5%N/A6.2 $2.39 3/15/202425,910,000 shares $57.52 million +7.1%N/A4.5 $2.22 2/29/202424,200,000 shares $55.18 million -4.4%N/A4.1 $2.28 2/15/202425,320,000 shares $72.16 million -10.0%N/A4.3 $2.85 1/31/202428,130,000 shares $60.48 million +2.6%N/A4.1 $2.15 1/15/202427,430,000 shares $70.50 million +13.2%N/A3.8 $2.57 12/31/202324,230,000 shares $80.69 million +1.9%N/A3.9 $3.33 12/15/202323,770,000 shares $51.58 million +10.8%N/A4.5 $2.17Washington prepares for war (Ad)While the headlines obsess over overseas conflicts, Washington has been quietly preparing for something much bigger here at home. Emergency powers are being invoked, trillions are being mobilized, and the scale rivals anything we’ve seen since WWII. According to Porter Stansberry and Jeff Brown, a new economic arms race is already underway — one that could reshape markets, redirect capital, and impact billions of lives. They’ve just released an urgent briefing that explains what’s really happening behind the scenes, and which companies are positioned to benefit most.Click here now to watch the urgent wartime exposé 11/30/202321,460,000 shares $45.71 million -1.1%N/A4.9 $2.13 11/15/202321,690,000 shares $39.04 million +9.3%N/A5.1 $1.80 10/31/202319,840,000 shares $66.46 million +6.0%N/A5.3 $3.35 10/15/202318,720,000 shares $71.32 million +6.4%N/A7 $3.81 9/30/202317,600,000 shares $65.82 million +21.1%N/A6.1 $3.74 9/15/202314,530,000 shares $71.49 million -7.2%N/A4.9 $4.92 8/31/202315,650,000 shares $83.41 million -0.3%N/A4.8 $5.33 8/15/202315,700,000 shares $70.18 million +16.7%N/A4.6 $4.47 7/31/202313,450,000 shares $64.83 million +6.9%N/A3.5 $4.82 7/15/202312,580,000 shares $51.07 million -16.4%N/A3.7 $4.06 6/30/202315,040,000 shares $64.22 million +15.4%N/A4.8 $4.27 6/15/202313,030,000 shares $70.23 million +0.2%N/A4.7 $5.39 5/31/202313,010,000 shares $53.21 million +9.3%N/A6.5 $4.09 5/15/202311,900,000 shares $58.19 million +12.9%N/A7.7 $4.89 4/30/202310,540,000 shares $76.20 million -4.1%N/A9.9 $7.23 4/15/202310,990,000 shares $86.60 million -7.3%N/A11.1 $7.88 3/31/202311,850,000 shares $81.05 million -1.7%N/A11.2 $6.84 3/15/202312,050,000 shares $77.00 million +22.5%N/A9.6 $6.39 2/28/20239,840,000 shares $66.62 million +0.8%N/A8 $6.77 2/15/20239,760,000 shares $77.01 million +2.3%13.4%8.5 $7.89 1/31/20239,540,000 shares $80.90 million -6.2%13.1%7.7 $8.48 1/15/202310,170,000 shares $106.28 million +2.1%14.0%8.1 $10.45 12/30/20229,960,000 shares $78.88 million +2.9%13.7%8 $7.92 12/15/20229,680,000 shares $71.15 million -4.4%13.3%9.2 $7.35 11/30/202210,130,000 shares $69.49 million +1.5%13.9%10 $6.86 11/15/20229,980,000 shares $79.44 million +7.1%13.7%9.2 $7.96 10/31/20229,320,000 shares $81.08 million +0.3%12.8%9 $8.70 10/15/20229,290,000 shares $76.92 million -3.4%12.8%8.6 $8.28 9/30/20229,620,000 shares $92.45 million +2.3%13.2%8.9 $9.61 9/15/20229,400,000 shares $98.98 million -1.2%12.9%8.5 $10.53 8/31/20229,510,000 shares $106.32 million -8.6%13.1%8.6 $11.18 8/15/202210,400,000 shares $144.25 million -1.8%14.3%9.8 $13.87 7/31/202210,590,000 shares $89.70 million +7.5%14.6%9.5 $8.47 7/15/20229,850,000 shares $78.50 million -10.4%13.6%9.2 $7.97 6/30/202210,990,000 shares $79.57 million +13.1%15.2%10.4 $7.24 6/15/20229,720,000 shares $58.22 million -4.6%13.4%9.4 $5.99 5/31/202210,190,000 shares $74.79 million +0.8%14.1%10.8 $7.34 5/15/202210,110,000 shares $80.37 million +16.2%14.0%11.1 $7.95 4/30/20228,700,000 shares $78.65 million +13.7%12.0%9.8 $9.04 4/15/20227,650,000 shares $85.99 million +0.1%10.6%8.7 $11.24 3/31/20227,640,000 shares $98.63 million +9.0%10.6%8.6 $12.91 3/15/20227,010,000 shares $87.91 million -1.3%9.7%8.1 $12.54 2/28/20227,100,000 shares $83.71 million -5.2%9.9%8.2 $11.79 2/15/20227,490,000 shares $98.87 million +13.8%10.4%8.6 $13.20 1/31/20226,580,000 shares $81.33 million -4.1%9.2%8.3 $12.36 1/15/20226,860,000 shares $95.35 million -3.7%9.6%9.7 $13.90 12/31/20217,120,000 shares $113.64 million +4.4%9.9%11.4 $15.96 12/15/20216,820,000 shares $117.24 million -4.5%9.5%10.6 $17.19 11/30/20217,140,000 shares $132.59 million +1.4%9.9%11.2 $18.57 11/15/20217,040,000 shares $133.20 million -6.3%9.8%10.9 $18.92Washington prepares for war (Ad)While the headlines obsess over overseas conflicts, Washington has been quietly preparing for something much bigger here at home. Emergency powers are being invoked, trillions are being mobilized, and the scale rivals anything we’ve seen since WWII. According to Porter Stansberry and Jeff Brown, a new economic arms race is already underway — one that could reshape markets, redirect capital, and impact billions of lives. They’ve just released an urgent briefing that explains what’s really happening behind the scenes, and which companies are positioned to benefit most.Click here now to watch the urgent wartime exposé 10/29/20217,510,000 shares $125.64 million -0.1%10.5%10.9 $16.73 10/15/20217,520,000 shares $127.84 million +1.5%10.5%11.5 $17.00 9/30/20217,410,000 shares $119.08 million -13.4%10.4%10.7 $16.07 9/15/20218,560,000 shares $135.16 million -11.9%12.0%12.9 $15.79 8/31/20219,720,000 shares $155.33 million +5.4%13.7%15.1 $15.98 8/13/20219,220,000 shares $128.43 million -1.3%13.0%13.5 $13.93 7/30/20219,340,000 shares $121.89 million +0.2%13.3%13.3 $13.05 7/15/20219,320,000 shares $122.37 million -2.0%13.2%12.4 $13.13 6/30/20219,510,000 shares $131.52 million -1.9%13.5%12.1 $13.83 6/15/20219,690,000 shares $136.73 million -3.2%13.8%11.1 $14.11 5/28/202110,010,000 shares $131.73 million -5.3%14.1%11.1 $13.16 5/14/202110,570,000 shares $146.82 million -5.4%N/A10 $13.89 4/30/202111,170,000 shares $164.20 million -16.8%16.4%10.3 $14.70 4/15/202113,420,000 shares $186.00 million -3.0%19.7%10.2 $13.86 3/31/202113,840,000 shares $199.99 million +1.9%20.3%10.2 $14.45 3/15/202113,580,000 shares $220.68 million +1.2%19.9%10 $16.25 2/26/202113,420,000 shares $204.66 million +2.6%19.7%10.2 $15.25 2/12/202113,080,000 shares $246.17 million -2.3%19.4%11.5 $18.82 1/29/202113,390,000 shares $259.77 million -11.3%19.8%12.2 $19.40 1/15/202115,100,000 shares $271.65 million -2.5%22.4%15.2 $17.99 12/31/202015,490,000 shares $272.16 million +6.1%22.9%17.6 $17.57 12/15/202014,600,000 shares $265.28 million -3.9%21.6%17.2 $18.17 11/30/202015,190,000 shares $282.84 million -3.6%22.5%17.2 $18.62 11/15/202015,760,000 shares $281.16 million -3.1%23.3%17.8 $17.84 10/30/202016,260,000 shares $278.86 million -3.0%24.1%17.9 $17.15 10/15/202016,770,000 shares $306.56 million -5.6%25.1%17.4 $18.28 9/30/202017,760,000 shares $325.72 million -5.9%26.5%18.4 $18.34 9/15/202018,870,000 shares $353.06 million +1.6%28.5%18.7 $18.71 CHRS Short Interest - Frequently Asked Questions What is Coherus Oncology's current short interest? Short interest is the volume of Coherus Oncology shares that have been sold short but have not yet been covered or closed out. As of July 31st, traders have sold 32,340,000 shares of CHRS short. 30.35% of Coherus Oncology's shares are currently sold short. Learn More on Coherus Oncology's current short interest. What is a good short interest ratio for Coherus Oncology? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. CHRS shares currently have a short interest ratio of 23.0. Learn More on Coherus Oncology's short interest ratio. Which institutional investors are shorting Coherus Oncology? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Coherus Oncology: Group One Trading LLC, and Simplex Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Coherus Oncology? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 30.35% of Coherus Oncology's floating shares are currently sold short. Is Coherus Oncology's short interest increasing or decreasing? Coherus Oncology saw a increase in short interest in the month of July. As of July 31st, there was short interest totaling 32,340,000 shares, an increase of 3.6% from the previous total of 31,230,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Coherus Oncology's short interest compare to its competitors? 30.35% of Coherus Oncology's shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Coherus Oncology: AnaptysBio, Inc. (38.01%), Savara Inc. (26.09%), Sage Therapeutics, Inc. (4.03%), Rapport Therapeutics, Inc. (17.48%), Kodiak Sciences Inc. (5.18%), Arvinas, Inc. (10.84%), Gossamer Bio, Inc. (8.84%), Zevra Therapeutics, Inc. (8.59%), Opthea Limited Unsponsored ADR (0.36%), aTyr Pharma, Inc. (26.83%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($70.87 billion), Invesco QQQ ($30.12 billion), iShares Russell 2000 ETF ($19.85 billion), iShares 20+ Year Treasury Bond ETF ($10.34 billion), Strategy Inc ($8.98 billion), iShares iBoxx $ Investment Grade Corporate Bond ETF ($7.61 billion), SPDR S&P Biotech ETF ($6.81 billion), Invesco S&P 500 Equal Weight ETF ($6.14 billion), Palo Alto Networks, Inc. ($5.97 billion), and Super Micro Computer, Inc. ($5.28 billion). View all of the most shorted stocks. What does it mean to sell short Coherus Oncology stock? Short selling CHRS is an investing strategy that aims to generate trading profit from Coherus Oncology as its price is falling. CHRS shares are trading down $0.02 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Coherus Oncology? A short squeeze for Coherus Oncology occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of CHRS, which in turn drives the price of the stock up even further. How often is Coherus Oncology's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including CHRS, twice per month. The most recent reporting period available is July, 31 2025. More Short Interest Resources from MarketBeat Related Companies ANAB Short Interest Data SVRA Short Interest Data SAGE Short Interest Data RAPP Short Interest Data KOD Short Interest Data ARVN Short Interest Data GOSS Short Interest Data ZVRA Short Interest Data OPT Short Interest Data ATYR Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:CHRS) was last updated on 9/1/2025 by MarketBeat.com Staff From Our PartnersNew law could create $3.7 trillion tsunami.During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe $365M annual revenue crypto play While Bitcoin generates zero operational revenue, one DeFi protocol qu...Crypto 101 Media | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredOne tiny company just cracked Google’s $19B problemAn MIT lab recently cracked a code scientists had been chasing for decades… Turning a “miracle metal” from ...True Market Insiders | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Coherus Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Coherus Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
